NASDAQ:TNYA Tenaya Therapeutics (TNYA) Stock Price, News & Analysis $3.88 -0.11 (-2.76%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$3.58▼$4.0650-Day Range$2.72▼$4.5452-Week Range$1.66▼$7.01Volume305,757 shsAverage Volume465,619 shsMarket Capitalization$304.65 millionP/E RatioN/ADividend YieldN/APrice Target$15.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Tenaya Therapeutics alerts: Email Address Tenaya Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside286.6% Upside$15.00 Price TargetShort InterestBearish6.73% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.73Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.59) to ($1.57) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.04 out of 5 starsMedical Sector623rd out of 936 stocksBiological Products, Except Diagnostic Industry101st out of 154 stocks 3.5 Analyst's Opinion Consensus RatingTenaya Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageTenaya Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Tenaya Therapeutics' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted6.73% of the float of Tenaya Therapeutics has been sold short.Short Interest Ratio / Days to CoverTenaya Therapeutics has a short interest ratio ("days to cover") of 12.4, which indicates bearish sentiment.Change versus previous monthShort interest in Tenaya Therapeutics has recently increased by 12.85%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldTenaya Therapeutics does not currently pay a dividend.Dividend GrowthTenaya Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TNYA. Previous Next 2.6 News and Social Media Coverage News SentimentTenaya Therapeutics has a news sentiment score of 0.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Tenaya Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for TNYA on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Tenaya Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Tenaya Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders32.76% of the stock of Tenaya Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions90.54% of the stock of Tenaya Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Tenaya Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Tenaya Therapeutics are expected to grow in the coming year, from ($1.59) to ($1.57) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Tenaya Therapeutics is -2.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Tenaya Therapeutics is -2.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTenaya Therapeutics has a P/B Ratio of 1.89. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Tenaya Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About Tenaya Therapeutics Stock (NASDAQ:TNYA)Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.Read More TNYA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TNYA Stock News HeadlinesJuly 26 at 6:10 PM | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Dexcom (DXCM), Tenaya Therapeutics (TNYA) and Cue Biopharma (CUE)July 25 at 1:21 AM | americanbankingnews.comBrokerages Set Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Target Price at $15.00July 27, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.June 27, 2024 | globenewswire.comTenaya Therapeutics Announces Research Leadership UpdatesJune 18, 2024 | globenewswire.comTenaya Therapeutics to Participate at the TD Cowen Genetic Medicines & RNA SummitMay 25, 2024 | finance.yahoo.comWe're Keeping An Eye On Tenaya Therapeutics' (NASDAQ:TNYA) Cash Burn RateMay 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for Tenaya Therapeutics on Strong Program Prospects and Financial StabilityMay 15, 2024 | investorplace.comTNYA Stock Earnings: Tenaya Therapeutics Beats EPS for Q1 2024July 27, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.May 14, 2024 | marketwatch.comTenaya Therapeutics Cutting Workforce by 22%May 14, 2024 | globenewswire.comTenaya Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 2, 2024 | globenewswire.comTenaya Therapeutics to Highlight Growing Capabilities in Capsid Engineering, Gene Editing and Manufacturing at the American Society of Gene and Cell Therapy 27th Annual MeetingApril 14, 2024 | finance.yahoo.comInstitutions own 33% of Tenaya Therapeutics, Inc. (NASDAQ:TNYA) shares but private equity firms control 44% of the companyApril 5, 2024 | markets.businessinsider.comTenaya Therapeutics’ Strategic Advantages in Cardiovascular Genetic Medicine Garner Buy RatingMarch 29, 2024 | markets.businessinsider.comOptimistic Buy Rating for Tenaya Therapeutics Based on Promising Gene Therapy Pipeline and Upcoming Clinical MilestonesMarch 26, 2024 | finance.yahoo.com20 Countries with the Highest Heart Disease Deaths Per CapitaMarch 21, 2024 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Vera Therapeutics (VERA), Tyra Bioscience (TYRA) and Tenaya Therapeutics (TNYA)March 21, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Sera Prognostics (SERA), Tenaya Therapeutics (TNYA)See More Headlines Receive TNYA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tenaya Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today7/26/2024Next Earnings (Estimated)8/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TNYA CUSIPN/A CIK1858848 Webwww.tenayatherapeutics.com Phone650-825-6990FaxN/AEmployees110Year FoundedN/APrice Target and Rating Average Stock Price Target$15.00 High Stock Price Target$20.00 Low Stock Price Target$7.00 Potential Upside/Downside+286.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($1.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-124,080,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-76.38% Return on Assets-64.75% Debt Debt-to-Equity RatioN/A Current Ratio6.72 Quick Ratio6.72 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.05 per share Price / Book1.89Miscellaneous Outstanding Shares78,518,000Free Float52,796,000Market Cap$304.65 million OptionableOptionable Beta2.42 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. Faraz Ali M.B.A. (Age 51)CEO & Director Comp: $890.06kDr. Deepak Srivastava M.D. (Age 57)Scientific Founder, Chairman of Scientific Advisory Board & Director Comp: $120.5kMs. Leone D. Patterson M.B.A. (Age 62)Chief Financial & Business Officer Comp: $619.38kDr. Whittemore G. Tingley M.D. (Age 56)PH.D., Chief Medical Officer Comp: $645.79kDr. Eric N. Olson Ph.D.Scientific Founder & Member of Scientific Advisory BoardDr. Bruce R. ConklinScientific FounderDr. Saptarsi Haldar M.D.Scientific FounderDr. Sheng Ding Ph.D.Scientific FounderDr. Benoit G. Bruneau Ph.D.Scientific FounderDr. Kee-Hong Kim Ph.D. (Age 58)Chief Technology Officer More ExecutivesKey CompetitorsAdaptimmune TherapeuticsNASDAQ:ADAPuniQureNASDAQ:QUREPrecigenNASDAQ:PGENAbsciNASDAQ:ABSIBioAtlaNASDAQ:BCABView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 26,103 shares on 7/26/2024Ownership: 0.303%Atticus Wealth Management LLCSold 25,949 shares on 7/17/2024Ownership: 0.039%RA Capital Management L.P.Bought 247,703 shares on 5/17/2024Ownership: 7.329%Jacobs Levy Equity Management Inc.Bought 80,212 shares on 5/16/2024Ownership: 0.215%Price T Rowe Associates Inc. MDSold 1,198,021 shares on 5/15/2024Ownership: 4.262%View All Insider TransactionsView All Institutional Transactions TNYA Stock Analysis - Frequently Asked Questions How have TNYA shares performed this year? Tenaya Therapeutics' stock was trading at $3.24 on January 1st, 2024. Since then, TNYA stock has increased by 19.8% and is now trading at $3.88. View the best growth stocks for 2024 here. How were Tenaya Therapeutics' earnings last quarter? Tenaya Therapeutics, Inc. (NASDAQ:TNYA) announced its earnings results on Tuesday, May, 14th. The company reported ($0.40) earnings per share for the quarter, topping the consensus estimate of ($0.43) by $0.03. When did Tenaya Therapeutics IPO? Tenaya Therapeutics (TNYA) raised $150 million in an initial public offering (IPO) on Friday, July 30th 2021. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. Who are Tenaya Therapeutics' major shareholders? Top institutional investors of Tenaya Therapeutics include Bank of New York Mellon Corp (0.30%) and Atticus Wealth Management LLC (0.04%). Insiders that own company stock include Group Gp Lp Column III, David V Goeddel, Deepak Srivastava, Timothy Hoey and Faraz Ali. View institutional ownership trends. How do I buy shares of Tenaya Therapeutics? Shares of TNYA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TNYA) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredFormer Hedge Fund Manager Issues Crash PredictionOur No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tenaya Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tenaya Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
